Market closedNon-fractional
Precision BioSciences/DTIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Ticker
DTIL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Durham, United States
Employees
109
Website
www.precisionbiosciences.com
DTIL Metrics
BasicAdvanced
$64M
Market cap
-
P/E ratio
-$6.62
EPS
1.74
Beta
-
Dividend rate
Price and volume
Market cap
$64M
Beta
1.74
Financial strength
Current ratio
4.824
Quick ratio
4.185
Long term debt to equity
19.919
Total debt to equity
83.462
Interest coverage (TTM)
-15.15%
Management effectiveness
Return on assets (TTM)
-11.10%
Return on equity (TTM)
-51.66%
Valuation
Price to revenue (TTM)
0.668
Price to book
1.69
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
-0.525
Growth
Revenue change (TTM)
88.25%
Earnings per share change (TTM)
-79.59%
3-year revenue growth
19.59%
3-year earnings per share growth
-51.12%
What the Analysts think about DTIL
Analyst Ratings
Majority rating from 6 analysts.
DTIL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
150.00%
Net income
$8.5M
-152.47%
Profit margin
48.57%
-120.99%
DTIL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.00
-$2.10
-$4.06
$1.70
-
Expected
-$7.32
-$4.88
-$2.05
-$1.91
-$1.51
Surprise
-59.02%
-56.92%
98.29%
-188.85%
-
DTIL News
AllArticlesVideos
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Business Wire·1 month ago
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precision BioSciences stock?
Precision BioSciences (DTIL) has a market cap of $64M as of July 06, 2024.
What is the P/E ratio for Precision BioSciences stock?
The price to earnings (P/E) ratio for Precision BioSciences (DTIL) stock is 0 as of July 06, 2024.
Does Precision BioSciences stock pay dividends?
No, Precision BioSciences (DTIL) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Precision BioSciences dividend payment date?
Precision BioSciences (DTIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Precision BioSciences?
Precision BioSciences (DTIL) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Precision BioSciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.